Aktie A3CRYC KETAMINEONE CAPITAL
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen KetamineOne Capital Deutsche Boerse AG

Aktien

A3CRYC

CA4925531028

MY00

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group
Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval
Wellbeing Announces Cease Trade Order
IIROC Trading Halt - MEDI
Wellbeing Provides Bi-Weekly Default Status Report
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
Wellbeing Digital to Participate in The Global Biomedical Design Conference
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
Wellbeing Provides Bi-Weekly Default Status Report
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
Wellbeing Provides Bi-Weekly Default Status Report
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QBS0 Aktie
  4. A3CRYC Aktie
  5. Nachrichten KetamineOne Capital
  6. Andere Sprachen